SNSE
Income statement / Annual
Last year (2023), Sensei Biotherapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Sensei Biotherapeutics, Inc.'s net income was -$34.10 M.
See Sensei Biotherapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$571,000.00 |
$1.81 M |
$685,000.00 |
$209,000.00 |
$73,000.00 |
$44,000.00 |
| Gross Profit |
-$571,000.00 |
-$1.81 M |
-$685,000.00 |
-$209,000.00 |
-$73,000.00 |
-$44,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$18.30 M
|
$30.38 M
|
$21.66 M
|
$11.19 M
|
$8.35 M
|
$8.23 M
|
| General & Administrative
Expenses |
$18.67 M
|
$19.81 M
|
$15.82 M
|
$7.53 M
|
$4.09 M
|
$4.51 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$18.67 M
|
$19.81 M
|
$15.82 M
|
$7.53 M
|
$4.09 M
|
$4.51 M
|
| Other Expenses |
$0.00 |
$1.60 M |
$688,000.00 |
-$649,000.00 |
-$1,000.00 |
$28,000.00 |
| Operating Expenses |
$37.06 M |
$50.19 M |
$37.48 M |
$18.71 M |
$12.44 M |
$12.74 M |
| Cost And Expenses |
$37.06 M |
$50.19 M |
$37.48 M |
$18.71 M |
$12.44 M |
$12.74 M |
| Interest Income |
$3.62 M |
$1.78 M |
$800,000.00 |
$1,689.00 |
$2,256.00 |
$0.00 |
| Interest Expense |
$144,000.00 |
$219,000.00 |
$670,000.00 |
$1.69 M |
$2.26 M |
$327,000.00 |
| Depreciation &
Amortization |
$3.68 M
|
$1.81 M
|
$685,000.00
|
$209,000.00
|
$73,000.00
|
$44,000.00
|
| EBITDA |
-$33.39 M
|
-$46.56 M
|
-$36.80 M
|
-$18.50 M
|
-$12.36 M
|
-$12.70 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$2.96 M
|
$1.60 M
|
$688,000.00
|
-$649,000.00
|
-$4.31 M
|
-$299,000.00
|
| Income Before Tax |
-$34.10 M |
-$48.59 M |
-$36.79 M |
-$20.10 M |
-$16.74 M |
-$13.04 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$219,000.00 |
$670,000.00 |
$529,000.00 |
$2.26 M |
$299,000.00 |
| Net Income |
-$34.10 M |
-$48.81 M |
-$37.46 M |
-$20.63 M |
-$19.00 M |
-$13.04 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.22 |
-1.59 |
-1.35 |
-0.67 |
-0.65 |
-19.03 |
| EPS Diluted |
-1.22 |
-1.59 |
-1.35 |
-0.67 |
-0.65 |
-19.03 |
| Weighted Average Shares
Out |
$27.95 M
|
$30.70 M
|
$27.71 M
|
$30.59 M
|
$29.33 M
|
$685,164.00
|
| Weighted Average Shares
Out Diluted |
$27.95 M
|
$30.70 M
|
$27.71 M
|
$30.59 M
|
$29.33 M
|
$685,164.00
|
| Link |
|
|
|
|
|
|
